Truist lowered the firm’s price target on Insmed (INSM) to $185 from $205 and keeps a Buy rating on the shares. The firm updated its model following Q1 results, incorporating recent competitive developments and refining Brinsupri estimates based on post-earnings physician feedback, the analyst tells investors.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: